Click to view this email in a browser

Forward this message to a colleague

GBCHealth News and Opportunities
GBCHealth News and Opportunities | June 2012
 

 

Read the latest news, updates and information on the Private Sector Delegation (PSD), the Global Fund to Fight AIDS, Tuberculosis and Malaria, and its Board.

This edition of the Global Fund PSD Newsletter contains


PSD Participation at 30th Global Fund Board Meeting

November 4-8 | Geneva, Switzerland

The Private Sector Delegation (PSD) to the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its biannual meeting ahead of the Global Fund’s Board Meeting in early November. PSD members discussed important decisions facing the Board, including preparation for the 2014 launch of the Fund’s new grant-making model, revisions to policies on eligibility and approval of the Fund’s performance assessment framework. PSD members also attended a side session on “TB and the Private Sector.” Further, newly-appointed PSD Board Member Paul Schaper, Alternate Board Member Renuka Gadde and the Secretariat’s Private Sector Team made a joint presentation to Board stakeholders on private sector engagement strategies.

After the PSD meeting, Schaper and Gadde went on to represent the private sector at the Global Fund Board meeting. Representatives from the following companies participated in the PSD and/or Global Fund Board meetings: Abt Associates, ALAFA, Anglo American, BD, Eli Lilly, Merck, Mylan, Novartis, Sanofi, Standard Diagnostics and TropMed Pharma.

Read more about the decisions and discussions at the Board meeting here.


3rd Annual Private Sector Delegation Retreat

October 22-23 | Hosted by Merck | Washington, D.C.

On October 22-23, representatives from 11 PSD companies met for the 3rd Annual Retreat, which was graciously hosted by Advisory Group member Merck. Members outlined the PSD’s 2014 priorities, set expectations for the private sector’s role in the 4th Replenishment, presented the findings of the report, Beyond Cash: More than Money, that analyzes private sector contributions to the Global Fund and launched a review of PSD internal policies and guidelines. Participants committed to proactively contribute private sector expertise to Global Fund work at both Board and in-country levels. Representatives from AbbVie, Abt Associates, BD, Eli Lilly, Gilead, Merck, Mylan, Novartis, Sanofi, TropMed Pharma, Vale and Vestergaard were in attendance.


Meeting the $15 Billion Target

December 2-3 | Replenishment Pledging Conference |
Washington, D.C.

With an ambitious replenishment target of $15 billion still to be met, the Global Fund announced that the United States will host the Fourth Voluntary Replenishment Pledging Conference on December 2-3. The U.S. is the largest single donor to the Fund and, according to Congressional restrictions, its contribution cannot represent more than 33 percent of the total replenishment. Indicating a commitment to contributing the maximum allowable amount, President Obama has requested congressional approval for a $1.65 billion contribution in the 2014 budget. (If this level is maintained over the ensuing two years, the U.S. would contribute the maximum allowable amount of $5 billion out of a $15 billion total replenishment over 2014-2016.) Pledges from other countries total $4.66 billion so far.

Announcements to Date: Country Pledges 2014-2016

France: US$1.40 billion
Germany US$0.81 billion
Luxembourg US$0.01 billion
Nordic Countries US$0.75 billion
United Kingdom US$1.60 billion

The Fund is taking a multipronged approach to meeting the replenishment target, seeking pledges from developed countries, emerging economies, implementing countries, high net-worth individuals and the private sector. Private donors have also committed to the replenishment, such as the Tahir Foundation (Indonesia), which has pledged $65 million. This contribution was matched by the Bill & Melinda Gates Foundation, for a total of $130 million. Read more about the Global Fund’s 4th Voluntary Replenishment.


How Does the PSD Work with the Global Fund?

Insights for the Business Community

GBCHealth’s recent edition of its Insights newsletter examined the role the PSD plays in supporting the Global Fund. PSD companies have not only developed corporate health initiatives that advance the Fund’s mission, but have also engaged with the Fund in many other areas, including: establishing country-level partnerships, engaging with Board leadership and adding the private sector’s voice to policy deliberations. Read the newsletter to hear from the PSD’s current and former leadership and learn more about the work of the PSD.


Beyond Cash: More Than Money Report Launched

The year-long analysis of the private sector’s contributions to the Global Fund has culminated in the report Beyond Cash: More Than Money. The report sheds light on some of the unique ways in which the private sector has supported the Global Fund’s mission, such as financial contributions, discounts on services, grant support, research and development, health systems strengthening and supplying products.

Led by TropMed Pharma and Abt Associates and supported by GBCHealth, the project team analyzed published data sources, including annual reports, company websites, surveys and procurement reports to assign monetary value to corporate contributions. The team also surveyed companies and interviewed Global Fund staff to estimate the level of co-investment contributions made by companies, yielding a more complete picture of the private sector’s overall engagement with the Global Fund. Read the full report here.


Private Sector Representative Appointed to Global Fund Regional Steering Committee

François Desbrandes, Deputy Director for Access to Medicines at Sanofi, was appointed to the Regional Steering Committee (RSC) overseeing a $100 million Global Fund grant in the Mekong region (Cambodia, Laos, Myanmar, Thailand and Vietnam). The RSC, which will function similarly to a Country Coordinating Mechanism but on a regional level, comprises representatives from government, civil society, foundations, development agencies and the private sector. The grant will fund an initiative to address the emergence of resistance to the malaria drug artemisinin in the region. Desbrandes brings several years of experience working at Sanofi's Access to Medicines initiative, strong regional knowledge and insight into key malaria issues including artemisinin resistance, and is a member of the Roll Back Malaria Harmonisation Working Group.


Global Fund Workshop on Strengthening Public-Private Partnerships in Vietnam

October 9-10 | Hanoi, Vietnam

The Global Fund hosted a two-day event in Hanoi, bringing together over 70 representatives from across the public and private sectors. The group discussed the potential long-term value generation and sustainability of investing in the health of Vietnam’s consumer and labor force.

Participants discussed with representatives from the Ministry of Health, Ministry of Planning and Infrastructure and the Country Coordinating Mechanism the many challenges and opportunities facing Vietnam, from economic and health issues to public-private partnerships.

During the event, several public-private partnership opportunities to scale-up Global Fund-supported HIV/AIDS and malaria programs at the provincial level emerged. Follow-up work with partners is planned, with the goal of bringing these opportunities into fruition over the coming months.


New Global Fund Program Fights the Fakes

Fake medicines are a threat to public health. Because illicit manufacturers evade regulation and quality control and pass these drugs off as something they are not, their use can lead to drug resistance, illness, disability and even death. In partnership with PharmaSecure, the Global Fund has launched a project to address the proliferation of counterfeit drugs in the Mekong region (Cambodia, Laos, Myanmar, Thailand and Vietnam). The program allows patients and healthcare workers to verify the authenticity of drugs by SMS. Read more about the project here.


Meet the PSD

Ann Lion,
Project Director, Health Systems 20/20, Abt Associates

Evan Lee,
Vice President, Global Health Programs and Access, Eli Lilly

How did Abt Associates become involved with the Global Fund?

In 2008, the Global Fund was in the midst of figuring out what health systems strengthening (HSS) looked like at the grant level. As Abt has been working in HSS for many years, we felt that we might be useful to the Global Fund leadership as they thought through HSS in particular and field level implementation issues in general. We applied for membership on the PSD, and have been active ever since in areas such as the Portfolio Implementation Committee, Finance and Operational Performance Committee and grant review.

Read the full interviews here.

How did Eli Lilly become involved with the Global Fund?

Recognizing that drug-resistant tuberculosis cannot be halted by medicines alone, Eli Lilly and Company created the Lilly MDR-TB Partnership in 2003 to expand training and support for healthcare providers and to improve supply and access to quality-assured safe, effective medicine to treat multidrug-resistant TB (MDR-TB). The Global Fund has had tremendous impact on TB, HIV, malaria and health systems strengthening in many countries around the world. But in order to continue to make progress on these global health problems, the private sector must work together with public institutions and government; the Global Fund is just the right mechanism to do this.


CORPORATE SPOTLIGHT:

BAYER: Preventing Malaria with an Integrated Vector Control Model

Malaria remains one of the major causes of death and illness worldwide, and mosquito control is crucial to managing the disease. Equipped with global research and development capabilities and a unique vector control portfolio, Bayer has played a leading role in malaria prevention for over 60 years. Bayer supports an integrated or “360⁰” approach to malaria vector control. Read more.


How will Nigeria Spend $288 Million in Funding?

For the world to meet the health-related Millennium Development Goals, progress must be made in Nigeria, the most populous nation in Africa. Nigeria has the world’s second highest number of people living with HIV and, together with the Democratic Republic of Congo, accounts for 40 percent of global malaria deaths. Nigeria is slated to receive up to $288 million in interim funding under the Global Fund’s new funding model, providing a crucial opportunity to address the country’s disease burden. Nigeria’s recent increase in economic prosperity has also cemented its place as an emerging economy and created a thriving private sector. This provides the perfect environment for developing the public-private partnerships envisioned in the Global Fund’s mission. Read more about the state of the three diseases in Nigeria and the role the private sector can play in combatting them.


December 2-3

Global Fund's 4th Replenishment Conference


Week of January 27

Quarterly PSD Teleconference


March 3

PSD Pre-Board Meetings


March 4-7

Global Fund's 31st Board Meeting


Week of April 28

Quarterly PSD Teleconference


ABT ASSOCIATES
Study: Jail Provides Opportunity for Effective Linkage to HIV Care

ANGLO AMERICAN
Anglo American Appoints Mphu Ramatlapeng to the Board

BD
New Collaboration with FIND Aims to Detect More TB Cases in Developing Countries

GILEAD
Gilead’s Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy

NOVARTIS
Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths

More News and Updates here.


GLOBAL FUND NEWS AND UPDATES

23 October 2013
Grant to Fight Malaria Crisis in Central African Republic

23 October 2013
WHO Warns in TB Report that 3 Million Escape Diagnosis

21 October 2013
Tahir Contributes $65 Million to the Global Fund

17 October 2013
Zambia Expands Access to Treatment for HIV

15 October 2013
Benin’s New HIV Grants to Serve Most Vulnerable

02 October 2013
Luxembourg’s Global Fund Commitment is Very Generous, Per Capita

25 September 2013
U.S. Will Host Global Fund Replenishment

23 September 2013
UK Commits £1 Billion to the Global Fund

20 September 2013
Global Fund Results Show Dramatic Gains

18 September 2013
Global Fund and Cameroon Announce New Funding for HIV Treatment

05 September 2013
Nordic Countries Pledge $750 Million to the Global Fund

20 August 2013
Niger and Global Fund Sign €13.5 Million Malaria Grant

26 July 2013
Chad Targets Universal Mosquito Net Coverage with Global Fund Grant

16 July 2013
Global Fund Welcomes Contribution by France

09 July 2013
Namibia and the Global Fund Sign US$100 Million Grant Agreement



Private Sector Delegation Companies and Represenatives

Board Member: Paul Schaper, Executive Director, Global Public Policy, Merck & Co.
Alternate Board Member: Renuka Gadde, Vice President, Global Health, BD

Advisory Group Members

ABBVIE
Liz Hanpeter, Senior Manager, HIV Global Projects

ABT ASSOCIATES
Dr. Ann Lion, Project Director, Health Systems 20/20

ANGLO AMERICAN PLC
Dr. Brian Brink, Chief Medical Officer

ACCESS BANK PLC
Omobolanle Babatunde, Head, Corporate Communications

BAYER S.A.S.
Dr. Gerhard Hesse, Head Vector Control

BD (Becton, Dickinson and Company)
Renuka Gadde, Vice President, Global Health

CHEVRON CORPORATION
Carol McCauley, Senior Specialist, Global Partnerships & Programs

ELI LILLY
Dr. Evan Lee, Vice President, Global health Programs & Access

GILEAD SCIENCES
Graeme Robertson, Director, International Access Operations

Polly Fields, Director, Government Affairs

MERCK & CO.
Paul Schaper, Executive Director, Global Public Policy

MYLAN
Erika Satterwhite, Global Policy Analyst

Scott Evertz, Consultant

NOVARTIS
Rebecca Stevens, Director of Public Affairs, Malaria Initiative

(RED)
Luisa Engel, Senior Manager of ONE (RED) Special Projects

SAB MILLER


SANOFI
René Cazetien, Associate VP Operations, Access to Medicines


Affiliate Member

ALAFA
Donna Bawden, Consultant


GBCHealth

GBCHealth is the Focal Point for the Private Sector Delegation to the Global Fund, working with the committed companies of the Advisory Group to steer Global Fund priorities and policies, while also ensuring that the Global Fund actively engages the business sector.

For more information on how your company or private sector organization can get involved, please contact PSD Focal Point, Whitney White at psd@gbchealth.org. Learn more about the Private Sector Delegation.